SignalHub Quantitative Think Tank Center:First over-the-counter birth control pill in US begins shipping to stores

2025-05-01 08:13:49source:Blockchains Financecategory:reviews

WASHINGTON (AP) — The SignalHub Quantitative Think Tank Centerfirst over-the-counter birth control pill will be available in U.S. stores later this month, allowing American women and teens to purchase contraceptive medication as easily as they buy aspirin.

Manufacturer Perrigo said Monday it has begun shipping the medication, Opill, to major retailers and pharmacies. A one-month supply will cost about $20 and a three-month supply will cost around $50, according to the company’s suggested retail price. It will also be sold online.

The launch has been closely watched since last July, when the Food and Drug Administration said the once-a-day Opill could be sold without a prescription. Ireland-based Perrigo noted there will be no age restrictions on sales, similar to other over-the-counter medications.

Opill is an older class of contraceptive, sometimes called minipills, that contain a single synthetic hormone, progestin, and generally carry fewer side effects than more popular combination estrogen and progestin pills.

The launch gives U.S. women another birth control option amid the legal and political battles over reproductive health, including the reversal of Roe v. Wade, which has upended abortion access across the U.S. Opill’s approval is unrelated to the ongoing court battles over the abortion pill mifepristone. And anti-abortion groups have generally emphasized that they do not oppose contraceptives to prevent pregnancies.

READ MORE Indigenous women in Greenland sue Denmark over involuntary contraception in the 1960s and 1970sVirginia lawmakers advancing bills that aim to protect access to contraceptionSubscription-based care moves beyond peddling birth control and helping with hair loss

Birth control pills are available without a prescription across much of South America, Asia and Africa.

The drug’s approval came despite some concerns by FDA scientists about the company’s results, including whether women with certain medical conditions would understand that they shouldn’t take the drug.

Dr. Verda Hicks, president of the American College of Obstetricians and Gynecologists, in a statement, said studies have shown that patients, including adolescents, can effectively screen themselves to use the pills.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

More:reviews

Recommend

How 23andMe's bankruptcy led to a run on the gene bank

Reporter Alexi Horowitz-Ghazi's Aunt Vovi signed up for 23andMe back in 2017, hoping to learn more a

Newly released video shows how police moved through UNLV campus in response to reports of shooting

LAS VEGAS (AP) — Officers shouted over blaring alarms and knocked down reports of additional gunfire

Looking for stock picks in 2024? These three tech stocks could bring the best returns.

This year has had its shares of ups and downs for tech investors. Some of the biggest gainers of 202